| Ticker: | CAPR |
| Current Price: | $9.53 |
| % Daily Change: | -6.93% |
| Volume (1,000s): | 3,652.90 |
| Average Volume (1,000s): | 1,533.83 |
| Market Cap (M): | $551.90 |
| 1/2/2024 Price: | $5.12 |
| Change Since Inception: | 86.13% |
8840 Wilshire Boulevard
2nd Floor
Beverly Hills, CA 90211
United States
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company’s development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.